Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 9/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | ROR1 | Q01973 | 6/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14705592 | 0.85 | CSF1R (0.55) | ABL1CSF1RROR1DDR1 | |
| SCHEMBL24885728 | 0.82 | ABL1 (0.46) | ABL1CSF1RROR1DDR1 | |
| SCHEMBL22232727 | 0.80 | ABL1 (0.43) | ABL1CSF1RROR1DDR1 | |
| Trifluoroacetic Acid SCHEMBL30879813 | 0.78 | ABL1 (0.58) | ABL1CSF1RROR1DDR1 | |
| SCHEMBL16704334 | 0.73 | MKNK1 (0.46) | ABL1CSF1RROR1DDR1 | |
| SCHEMBL10207631 | 0.71 | MKNK1 (0.44) | ABL1CSF1RROR1DDR1 | |
| SCHEMBL22369939 | 0.70 | MKNK1 (0.46) | ABL1CSF1RROR1DDR1 | |
| SCHEMBL22232739 | 0.70 | ABL1 (0.41) | ABL1CSF1RROR1DDR1 | |
| SCHEMBL17471717 | 0.70 | CSF1R (0.57) | ABL1CSF1RROR1 | |
| SCHEMBL16085054 | 0.69 | RIPK1 (0.52) | ABL1CSF1RROR1DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284647-A1 | N-(3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYLPHENYL)-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR TREATING KINASE-RELATED DISEASES | VORONOI CO., LTD (KR) | 2021-09-16 | — | — | US | disclosed |
| US-20210284647-A1 | N-(3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYLPHENYL)-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR TREATING KINASE-RELATED DISEASES | VORONOI CO., LTD (KR) | 2021-09-16 | — | — | US | disclosed |
| WO-2020149553-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR TREATMENT OF KINASE-RELATED DISEASE | 주식회사 보로노이 | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284647-A1 | N-(3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYLPHENYL)-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR TREATING KINASE-RELATED DISEASES | MYLK3, MINK1, PLK2 | ABL1 163/4885CSF1R 1285/4885ROR1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.